Valneva SE
VALN9.270USD
+0.140+1.53%
終値 10/31, 16:00（ET）15分遅れの株価
1.51B時価総額
損失額直近12ヶ月PER
詳細情報 Valneva SE 企業名
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SEの企業情報
企業コードVALN
会社名Valneva SE
上場日Jun 28, 2007
最高経営責任者「CEO」Mr. Thomas Lingelbach
従業員数- -
証券種類Depository Receipt
決算期末Jun 28
本社所在地6 rue Alain Bombard
都市SAINT-HERBLAIN
証券取引所NASDAQ Global Select Consolidated
国France
郵便番号44800
電話番号33228073710
ウェブサイトhttps://valneva.com/
企業コードVALN
上場日Jun 28, 2007
最高経営責任者「CEO」Mr. Thomas Lingelbach
Valneva SEの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Hanneke Schuitemaker
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Daniele Guyot-Caparros
Ms. Daniele Guyot-Caparros
Independent Director
Independent Director
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Hanneke Schuitemaker
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
地域別USD
会社名
収益
比率
United States
48.59M
28.66%
Canada
32.32M
19.06%
United Kingdom
19.49M
11.49%
Germany
18.37M
10.84%
Austria
15.90M
9.37%
他の
34.91M
20.58%
事業別
地域別
事業別USD
会社名
収益
比率
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
株主
更新時刻: 21 hours ago
更新時刻: 21 hours ago
株主統計
種類
株主統計
株主統計
比率
Novo Holdings A/S
2.92%
Frazier Life Sciences Management, L.P.
1.80%
General American Investors Company, Inc.
0.44%
Wells Fargo Advisors
0.30%
Citadel Advisors LLC
0.04%
他の
94.50%
株主統計
株主統計
比率
Novo Holdings A/S
2.92%
Frazier Life Sciences Management, L.P.
1.80%
General American Investors Company, Inc.
0.44%
Wells Fargo Advisors
0.30%
Citadel Advisors LLC
0.04%
他の
94.50%
種類
株主統計
比率
Venture Capital
2.92%
Private Equity
1.80%
Investment Advisor
0.49%
Research Firm
0.31%
Hedge Fund
0.04%
他の
94.43%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
30
4.52M
5.57%
+3.60M
2025Q2
25
665.50K
0.82%
-300.83K
2025Q1
28
666.20K
0.82%
-333.59K
2024Q4
27
820.97K
1.18%
-47.15K
2024Q3
26
836.06K
1.21%
+31.78K
2024Q2
28
742.08K
1.07%
+162.52K
2024Q1
32
513.10K
0.74%
-47.53K
2023Q4
30
421.64K
0.61%
-110.65K
2023Q3
32
418.35K
0.60%
-285.66K
2023Q2
33
378.64K
0.55%
-602.57K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Novo Holdings A/S
2.38M
2.92%
+2.38M
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
1.46M
1.8%
+1.46M
--
Jun 30, 2025
General American Investors Company, Inc.
354.36K
0.44%
--
--
Jun 30, 2025
Wells Fargo Advisors
245.18K
0.3%
+1.96K
+0.81%
Jun 30, 2025
Citadel Advisors LLC
35.74K
0.04%
+8.52K
+31.30%
Jun 30, 2025
Ironwood Investment Management, LLC
25.14K
0.03%
+113.00
+0.45%
Jun 30, 2025
Marex Group plc
11.30K
0.01%
+11.30K
--
Jun 30, 2025
Morgan Stanley & Co. International Plc
6.54K
0.01%
+2.82K
+75.62%
Jun 30, 2025
VSM Wealth Advisory, LLC
4.00K
0%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
2.88K
0%
--
--
Aug 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
